Cell-specific active compounds regulated by the cell cycle

US6384202B1 · kind B1 · utility

Assignee

• Hoechst GmbH · DE

Inventors

• Hans-Harald Sedlacek · Marburg, DE
• Rolf Muller · Marburg, DE

Key dates

• Filing date: Apr 25, 1997
• Grant date: May 7, 2002
• Expiry date: Apr 25, 2017

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A DNA sequence is described for the gene therapy of diseases associated with the immune system. In its essential elements, the DNA sequence is composed of an activator sequence, a promoter module and a gene for the active substance. The activator sequence is activated in a cell-specific or virus-specific manner and this activation is regulated by the promoter module in a cell cycle-specific manner. The choice of activator sequence and active substance depends on the indication area. The DNA sequence is inserted into a viral or non-viral vector which is supplemented by a ligand having affinity for the target cell. Depending on the choice of activator sequence and active substance, the following can be treated by administering the DNA sequence: defective formation of blood cells; autoimmune diseases and allergies and, in addition, rejection reactions against transplanted organs; chronic arthritis; viral and parasitic infections and, in addition, prophylaxis of viral, bacterial and parasitic infections; and leukemias.